139,438 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Bought by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 139,438 shares of the medical research company’s stock, valued at approximately $71,877,000. Thermo Fisher Scientific makes up approximately 1.5% of Union Bancaire Privee UBP SA’s investment portfolio, making the stock its 19th largest holding.

A number of other hedge funds have also recently added to or reduced their stakes in TMO. Capital Asset Advisory Services LLC increased its holdings in Thermo Fisher Scientific by 2.1% in the 4th quarter. Capital Asset Advisory Services LLC now owns 6,075 shares of the medical research company’s stock worth $3,232,000 after purchasing an additional 127 shares in the last quarter. Blue Trust Inc. raised its holdings in Thermo Fisher Scientific by 39.6% in the 4th quarter. Blue Trust Inc. now owns 2,386 shares of the medical research company’s stock valued at $1,241,000 after buying an additional 677 shares during the last quarter. Maj Invest Holding A S bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $83,000. Novare Capital Management LLC raised its position in Thermo Fisher Scientific by 2.1% during the 4th quarter. Novare Capital Management LLC now owns 23,515 shares of the medical research company’s stock worth $12,233,000 after purchasing an additional 490 shares during the last quarter. Finally, Clarendon Private LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $440,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TMO shares. Stephens assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective on the stock. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Royal Bank of Canada lowered their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Redburn Atlantic started coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $648.95.

Insider Activity

In related news, CEO Marc N. Casper sold 5,850 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,611,804.88. This trade represents a 4.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders sold 34,850 shares of company stock valued at $19,123,197. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.1 %

TMO opened at $575.21 on Monday. The stock has a market cap of $220.02 billion, a PE ratio of 36.06, a P/E/G ratio of 3.82 and a beta of 0.76. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The business’s fifty day simple moving average is $533.60 and its 200 day simple moving average is $569.58.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific declared that its board has approved a share repurchase plan on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.